18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          LETTER Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), was reported for the first time in Wuhan (Hubei Province, China) in December 2019 (1, 2) and has become a major public health concern all over the world. Early diagnosis is crucial for patient management and outbreak control. Most tests currently used for the detection of SARS-CoV-2 rely on viral RNA amplification by using real-time PCR (RT-PCR) and require a few hours before result release. Hence, highly sensitive immunological diagnostic methods that directly detect viral antigens in clinical samples would be very helpful for rapid and accurate diagnosis of COVID-19. Here, we evaluated a rapid diagnostic test, COVID-19 Ag Respi-Strip (Coris BioConcept, Gembloux, Belgium), for detection of the SARS-CoV-2 antigen in nasopharyngeal secretions. The assay is ready to use and based on a nitrocellulose membrane technology with colloidal gold nanoparticles sensitized with monoclonal antibodies directed against highly conserved SARS-CoV-2 nucleoprotein antigens. We compared this test with RT-PCR, the current reference assay in virology laboratories of three university hospital groups from Assistance-Publique-Hôpitaux de Paris (APHP) (Saint-Antoine-Tenon-Trousseau, Saint-Louis-Lariboisière, and Kremlin Bicêtre-Paul Brousse). Different RT-PCR methods were used (RealStar [Altona Diagnostics], Bosphore novel coronavirus (2019-nCoV) detection kit [Anatolia Geneworks], Cobas 6800 [Roche], Allplex 2019 novel CoV assay [Seegene]). All assays amplify the SARS-CoV-2 E gene. Cycle threshold (CT ) values were recorded. Nasopharyngeal samples were tested prospectively within a few hours after collection and without any cooling or freezing step, from 1 April to 15 April 2020. Swabs were collected in various transport media (COPAN’s UTM [3 ml], Virocult [1 ml], ESwab Amies [1 ml], 4MRT [3 ml], 0.9% NaCl buffer, and cobas [Roche]). The first four samples collected in cobas medium tested gave invalid results. We therefore excluded such samples from the study. Our analysis included 138 nasopharyngeal samples, of which 94 (68.8%) were positive for SARS-CoV-2 by RT-PCR. Compared to that of RT-PCR, the specificity of the test was 100% (95% confidence intervals [95% CI], 91.8 to 100). Among the 94 RT-PCR-positive samples, the rapid test detected only 47 specimens, resulting in a sensitivity of 50.0% (95 CI, 39.5 to 60.5). In nine positive and eight negative tests, control lines were barely visible. Medians of E gene CT values differed significantly between positive (median = 21; interquartile range [IQR], 17.0 to 23.0) and negative (median = 28.3; IQR, 25.6 to 33.0) antigenic test results (P < 0.0001) (Fig. 1). A study conducted by the manufacturer mentioned a sensitivity of 76.7% for samples positive with a CT value under 25 (3). In our study, the test had a sensitivity of 82.2% for CT values under 25. FIG 1 COVID-19 Ag Respi-Strip (Coris) results according to real-time PCR CT values. All cycle threshold values of E gene real-time PCR-positive assays are shown for positive and negative COVID-19 Ag Respi-Strip assay results. Results gathering CT values for all real-time PCR-positive assays are depicted by squares. CT values between samples positive or negative for the antigenic assay are significantly different (* indicates a P value of <0.0001). CT values corresponding to the Cobas 6800, Allplex, Anatolia, and RealStar assays are depicted by triangles, diamonds, circles, and upside-down triangles, respectively. In our study, the COVID-19 Ag Respi-Strip (Coris) had a sensitivity of 50% compare to that of RT-PCR. The test was more sensitive for high viral loads and might perhaps be used for patients within a few days after symptom onset, when the load in the upper respiratory tract is at its peak. Considering COVID-19’s current low prevalence of 0.19% in France, prospective studies should be conducted to determine the best settings for its implementation.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A Novel Coronavirus from Patients with Pneumonia in China, 2019

            Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans. Enhanced surveillance and further investigation are ongoing. (Funded by the National Key Research and Development Program of China and the National Major Project for Control and Prevention of Infectious Disease in China.)
              Bookmark

              Author and article information

              Contributors
              Role: Editor
              Journal
              J Clin Microbiol
              J. Clin. Microbiol
              jcm
              jcm
              JCM
              Journal of Clinical Microbiology
              American Society for Microbiology (1752 N St., N.W., Washington, DC )
              0095-1137
              1098-660X
              13 May 2020
              23 July 2020
              August 2020
              23 July 2020
              : 58
              : 8
              : e00977-20
              Affiliations
              [a ]INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Paris, France
              [b ]Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France
              [c ]Hôpital Saint Louis, Laboratoire de Virologie, Paris, France
              [d ]Service de Virologie, Hôpital Paul-Brousse, INSERM U 1193, Université Paris-Saclay Villejuif, APHP Paris-Saclay, France
              [e ]Université de Paris, INSERM U976, Team Insight, Paris, France
              [f ]INSERM U944, Université de Paris, Paris, France
              Boston Children's Hospital
              Author notes
              Address correspondence to Sidonie Lambert-Niclot, sidonie.lambert@ 123456aphp.fr .

              Citation Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso A-M, Le Goff J, Delaugerre C, on behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration. 2020. Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. J Clin Microbiol 58:e00977-20. https://doi.org/10.1128/JCM.00977-20.

              Article
              00977-20
              10.1128/JCM.00977-20
              7383555
              32404480
              75f4d9e4-878f-41da-b346-c17d75471413
              Copyright © 2020 American Society for Microbiology.

              All Rights Reserved.

              This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

              History
              Page count
              Figures: 1, Tables: 0, Equations: 0, References: 3, Pages: 2, Words: 1145
              Categories
              Letter to the Editor
              Special Issue
              Custom metadata
              August 2020
              free

              Microbiology & Virology
              antigen,sars-cov-2,rapid diagnostic test
              Microbiology & Virology
              antigen, sars-cov-2, rapid diagnostic test

              Comments

              Comment on this article